A Phase 2 Proof-of-Concept Challenge Study Investigating EDP-938 in Respiratory-Syncytial-Virus (RSV) Infected Humans.

Trial Profile

A Phase 2 Proof-of-Concept Challenge Study Investigating EDP-938 in Respiratory-Syncytial-Virus (RSV) Infected Humans.

Planning
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2018

At a glance

  • Drugs EDP 938 (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 12 Feb 2018 New trial record
    • 07 Feb 2018 According to an Enanta Pharmaceuticals media release, upon successful completion of the phase I study (NCT03384823), this phase II proof-of-concept challenge study is expected to begin in the fourth quarter of calendar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top